Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2023)
56 slides from Genetic Technologies's shareholder meeting presentation, Nov 22, 2023
Slide 1: Annual General Meeting
Annual General Meeting November 22, 2023 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: How to ask a question
How to ask a question • To ask a written question select the Q&A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. 2
Slide 3: How to vote
How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 3
Slide 4: Agenda
Agenda • Chairman’s address – Mr Peter Rubinstein • Business of the Meeting • 2023 Annual Report and auditor’s report • Resolutions 1. Adoption of the Remuneration Report 2. Re-election Mr Peter Rubinstein 3. Re-election Dr Lindsay Wakefield 4. Approval of Increased Placement Capacity 5. Share Conso
Slide 5: Chairman's Address
Chairman's Address Mr. Peter Rubinstein 5
Slide 6: Items of business
Items of business First item of business: to receive and consider the company’s financial statements, directors’ report, and auditor’s report for the year ended 30 June 2023 6
Slide 7: Resolution 1: Adoption of the Remuneration Report
Resolution 1: Adoption of the Remuneration Report “That for the purpose of Section 250R(2) of the Corporations Act and all other purposes the Remuneration report as set out in the Directors’ report for the Company for the year ended 30 June 2023 be adopted.” 7
Slide 8: Resolution 1: Adoption of the Remuneration Report
Resolution 1: Adoption of the Remuneration Report • Proxy Voting: Vote type Voted % For 713,423,619 74.36 Against 242,779,122 25.30 Open-Usable 3,314,995 0.34 Abstain 445,477,664 8
Slide 9: Resolution 2: Re-Election of Mr Peter Rubinstein
Resolution 2: Re-Election of Mr Peter Rubinstein “To elect Mr Peter Rubinstein who retires by rotation in accordance with clause 20.3 of the Company’s Constitution and being eligible offers himself for re-election as a Director.” 9
Slide 10: Resolution 2: Re-Election of Mr Peter Rubinstein
Resolution 2: Re-Election of Mr Peter Rubinstein • Proxy Voting: Vote type Voted % For 1,588,619,984 84.71 Against 283,473,919 15.12 Open-Usable 3,314,995 0.17 Abstain 22,324,800 10
Slide 11: Resolution 3: Re-Election of Dr Lindsay Wakefield
Resolution 3: Re-Election of Dr Lindsay Wakefield “To elect Dr Lindsay Wakefield who retires by rotation in accordance with clause 20.3 of the Company’s Constitution and being eligible offers himself for re-election as a Director.” 11
Slide 12: Resolution 3: Re-Election of Dr Lindsay Wakefield
Resolution 3: Re-Election of Dr Lindsay Wakefield • Proxy Voting: Vote type Voted % For 1,608,801,251 84.95 Against 281,311,852 14.86 Open-Usable 3,564,995 0.19 Abstain 4,055,600 12
Slide 13: Resolution 4: Approval of Increased Placement Capacity
Resolution 4: Approval of Increased Placement Capacity “That pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the increase in capacity of the Company to issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the
Slide 14: Resolution 4: Approval of Increased Placement Capacity
Resolution 4: Approval of Increased Placement Capacity • Proxy Voting: Vote type Voted % For 1,314,827,290 69.86 Against 563,347,638 29.93 Open-Usable 4,064,995 0.21 Abstain 15,493,775 14
Slide 15: Resolution 5: Share Consolidation
Resolution 5: Share Consolidation “That, pursuant to section 254H(1) of the Corporations Act and for all other purposes, the issued capital of the Company be consolidated on the basis that every 100 Shares be consolidated into 1 Share and, where this consolidation results in a fraction of a Share be
Slide 16: Resolution 5: Share Consolidation
Resolution 5: Share Consolidation • Proxy Voting: Vote type Voted % For 1,296,603,927 68.43 Against 594,940,715 31.40 Open-Usable 3,314,995 0.17 Abstain 2,874,061 16
Slide 17: Resolution 6: Ratification of prior issue under Listing Rule 7.1
Resolution 6: Ratification of prior issue of Shares under ASX Listing Rule 7.1 That for the purposes of Listing Rule 7.4 and for all other purposes, approval is given for the prior issue by the Company of 1,385,094,771 Shares to U.S. institutional investors on 7 February 2023, as detailed in the Com
Slide 18: Resolution 6: Ratification of prior issue under Listing Rule 7.1
Resolution 6: Ratification of prior issue of Shares under ASX Listing Rule 7.1 • Proxy Voting: Vote type Voted % For 1,501,602,806 79.83 Against 376,181,712 20.00 Open-Usable 3,314,995 0.17 Abstain 16,634,185 18
Slide 19: Resolution 7: Ratification of prior issue under Listing Rule 7.1A
Resolution 7: Ratification of prior issue of Shares under ASX Listing Rule 7.1A “That for the purposes of Listing Rule 7.4 and for all other purposes, approval is given for the prior issue by the Company of 922,598,229 Shares to U.S. institutional investors on 7 February 2023, as detailed in the Com
Slide 20: Resolution 7: Ratification of prior issue under Listing Rule 7.1A
Resolution 7: Ratification of prior issue of Shares under ASX Listing Rule 7.1A • Proxy Voting: Vote type Voted % For 1,501,443,806 79.82 Against 370,301,312 19.68 Open-Usable 9,514,995 0.50 Abstain 16,473,585 20
Slide 21: Resolution 8: Issue of Warrants to H.C. Wainwright
Resolution 8: Issue of Warrants to H.C. Wainwright “That for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the issue of 250,000 Warrants to acquire ADSs, each representing 600 ordinary shares in the Company, to H.C. Wainwright & Co in part consideration for exclu
Slide 22: Resolution 8: Issue of Warrants to H.C. Wainwright
Resolution 8: Issue of Warrants to H.C. Wainwright • Proxy Voting: Vote type Voted % For 1,295,718,687 78.25 Against 358,038,987 21.62 Open-Usable 2,202,995 0.13 Abstain 241,773,029 22
Slide 23: Chief Executive Officer Address
Chief Executive Officer Address Mr. Simon Morriss The Future: Unlocking personalized preventative medicine 23
Slide 24: Notice: Forward looking statements
Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require fu
Slide 25: Key Messages
Key Messages • Executing our Vision and Strategy to be leader in personalized predictive genomics • Our journey from R&D Commercialization and the pathway to profitability • Milestones include: • Precision Medicine launch with Major Private Hospital • GeneType Multi-test with 3 NEW tests – Approve
Slide 26: Vision and unique value proposition
VISION World leader in personalized predictive genomics. Empowering individuals to take control of their health. UNIQUE VALUE PROPOSITION Turning cutting-edge science into personalized, predictive tests driven by AI & machine learning techniques. Backed by over 20 years of experience, our scientific
Slide 27: World leading portfolio
World leading portfolio Most comprehensive guideline driven portfolio for human and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic & Monogenic diseases • Pet care Revenues anchored by our 3 brands to
Slide 28: Global Overview
Global Overview 60 40 25 Employees Countries Patents Granted* (FTE) globally (9 Pending Worldwide*) 14 51 12 Test Tests Partner Categories Laboratories * Patents granted are specific to the GeneType portfolio of products 28
Slide 29: Delivering Revenue and Growth
Delivering Revenue and Growth – year ending 30 June 29% Growth CASH RECEIPTS on LY CASH BALANCE Cash Receipts (A$'000) $8,771 FY23 A$8.8m A$7.9m* $6,789 +29% GROSS MARGIN GROSS MARGIN $89 A$4.2m 47% Full Year FY21 Full Year FY22 Full Year FY23 Strategic & Operational Highlights: • Group receipts fro
Slide 30: Our Pathway to Profitability
Our Pathway to Profitability Our Journey from Extensive R&D to Revenue and Profitability Research, Development and Commercialisation and Pathway to Profitability Innovation Revenue Generation 2000 - 2024 - 2021 2022 2023 2021 2025 Pioneers in Genomics, Launched Patented Acquired Affinity DNA Global
Slide 31: Revenue Drivers and our Pathway to Profitability
Revenue Drivers and our Pathway to Profitability Q4 CY2024 Cash Flow positive* Launch UK Pharmacy April 2024 12 months worth of self funding cash Q4 FY2024 - BD, License Agreement Q3 CY2024 - Coding strategy & payment June’24 - NCCN guideline pathway to inclusion Q3 FY2024 Launch BD, License H1 FY20
Slide 32: Environmental, Social & Governance
Genetic Technologies ASX:GTG - ESG Focus Areas Environmental, Social & Governance Highlights: • Board and Executive teams clearly defined our vision and purpose • Introduced updated Maternity Leave Policy exceeding mandatory level, addressing Pay Equity • Conducted Cybersecurity Training, addressing
Slide 33: Major Milestones: Precision Medicine Launch
Major Milestones Precision Medicine Launch with Major Private Hospital Pioneering Precision Medicine - Prestigious initiative for the hospital Pilot study will utilise: • Patented geneType Multi-risk test Combining Clinical and Genetic risk • 9 Diseases - Oncology, Cardiovascular, and Metabolic risk
Slide 34: Major Milestones: Expanded geneType Multi-test Approved
Major Milestones Expanded geneType Multi-test Approved Announced that the expanded geneType Multi- Risk Test is now available to order in Australia. GTG announced the launch of the expanded test in the U.S., to include three new diseases, in March 2023. The three new diseases • Pancreatic Cancer • M
Slide 35: Major Milestones: Multi Cancer Risk trial
Major Milestones Sole Industry Partner in Multi Cancer Risk trial Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded. The grant will provide funding for a randomized controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic ri
Slide 36: Major Milestones: Pancreatic Cancer risk publication
Major Milestones Publication GeneType Predicting Risk of Pancreatic Cancer GeneType’s Pancreatic Cancer risk assessment showed nearly 50% improvement in identifying patients at high risk. The study evaluated close to 380,000 adults aged 40 to 69 years from the UK Biobank, identifying 851 incident ca
Slide 37: Ambassador - GeneType for Melanoma
Ambassador - GeneType for Melanoma Campaign to promoted the Early Detection of Melanoma Driving awareness of Melanoma in the Summer of 2023 focusing on TV, Radio and Print media Deborah revealed that the two cancers on her face were undetectable to the naked eye. Deborah's shares a graphic shot is a
Slide 38: Exploring NEW markets – Southeast Asia
Exploring NEW markets – Southeast Asia Exclusive networking event in Jakarta, Indonesia - Uniting innovation • The keynote address was by Budi Sadikin, Minister of Health, Ministry of Health of the Republic of Indonesia • Southeast Asian healthcare market projected to reach USD 270 Billion by 2027 P
Slide 39: Exploring NEW markets - UK Pharmacy Expansion
Exploring NEW markets - UK Pharmacy Expansion EasyDNA / Affinity DNA and Genetype • Across 10,000 geared at helping patients increase their general health and wellbeing. • The focus areas being disseminated through the NPA's 10,000+ pharmacies is Home Testing, where geneType / EasyDNA / Affinity DNA
Slide 40: Pathways to Market
Pathways to Market Executing a multi-brand strategy Medical & Payer Consumer initiated Direct to Consumer Business to testing (CIT) Testing (DTC) Business (B2B) with medical supervision with no medical supervision Oncology – GTG Expanded Carrier testing & NIPT [insert revenue structure Cardiovascula
Slide 41: B2B - US Enterprise model; market segmentation critical
B2B - US Enterprise model; market segmentation critical Driving our Revenue Pipeline 1. Current geneType CRM Contacts (~1,000) HCP Clinics 2. Functional Medicine Patient Pay 3. Concierge Medicine (3-6 months) 4. Longevity Clinics 5. Anti-Aging Clinics 6. Academic Precision Medicine Programs HCP-Cent
Slide 42: Our Innovation – Multi-Risk Test
Our Innovation – Multi-Risk Test GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment. GeneType Risk assessment test for breast cancer has demonstrated improved early-stage detection by 18% and saving approx. US$1.4B per annum4 for the US payer GeneType
Slide 43: NEW Comprehensive Breast and Ovarian Cancer test
NEW Comprehensive Breast and Ovarian Cancer test Evaluates a woman’s risk of developing Breast and/or Ovarian Cancer in women 30 years+ 5% - Hereditary Cancer with known pathogenic variant BRCA1/2 10% - Familial cancer with no known pathogenic variant 85% - geneType Patented integrated Breast and Ov
Slide 44: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and [insert revenue structure and agreement types] Brand Refreshagreement types] Website Refresh Improved Lead Gen New Sales Channels Product list Product list Multi-brand Portfolio
Slide 45: Collaborations
Collaborations Memorial Professor Bernard Professor Graham Professor John Professor Jon Ohio State Colditz Hopper Emery Sloane Kettering Rosner Cancer University Brigham & Women’s Deputy Director, Professorial Fellow at Professor of Primary Collaborating on a Collaborating on a Hospital and Harvard
Slide 46: Snapshot and Achievements last 12 months
Snapshot and Achievements last 12 months GeneType & Commercialization EasyDNA & Affinity DNA Reimbursement activation FY23 Group Receipts A$8.8 million, up 29% Integrated 2 Acquisitions Independently developed Budget Impact Model (BIM) identifies US$1.4 billion dollars in GeneType risk test:
Slide 47: Summary
Summary • Developed a clear Vision and Strategy to be leader in personalized predictive genomics • Identified the Drivers of Revenue and pathway to profitability by the middle of FY25 • Strong momentum in commercial operations with +29% growth in customer receipts • We have a global operation, a com
Slide 48: Thank you & Questions
Thank you & Questions Investor Relations Adrian Mulcahy Market Eye – Automic Group www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au www.genetype.com 48
Slide 49: Return to the Chairman
Return to the Chairman 49
Slide 50: Appendices
Appendices 50
Slide 51: Board and Management
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Comm, FAICD, FCA, Chairman Non – Executive Director FGIA, FTIA, F Fin Non – Executive Director Non – Executive Director Dr. Jerzy “George” Erika Spaeth Simon Mo
Slide 52: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Regional Medical Director
Slide 53: Financial Overview
Financial Overview • Net cash outflow of A$4.1 million for the 12 months to 30 June 2023. We continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialize our geneType tests • Cash reserves will be directed: A$’000 30-June-23 30-June-22 Change • to support the commercialization
Slide 54: Corporate Overview
Corporate Overview Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 23 October 2023 0.2c Other, 25% ADR price (USD) as at 23 October 2023 $0.70 Ord Shares on Issue (M) 11,542 ASX 52-week trading (AUD l
Slide 55: Our Intellectual Property
Our Intellectual Property 4 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of • Breast cancer risk assessment assessing risk of developing a severe • Methods for assessing risk of developing prostate cancer response to Coronavirus infection • Methods for asse
Slide 56: Defined Terms
Defined Terms Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score - a number associated
Genetic Technologies — Shareholder Meeting (November 2023) on 6ix